146 related articles for article (PubMed ID: 38758855)
1. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
Lin Y; Xu G; Li L; Xiang J; Zhai L
Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
[TBL] [Abstract][Full Text] [Related]
2. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
4. Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes.
Lu S; Yin H; Yu OHY; Azoulay L
Epidemiology; 2022 Jul; 33(4):563-571. PubMed ID: 35394977
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis.
Cui H; Wang Y; Yang S; He G; Jiang Z; Gang X; Wang G
Pharmacol Res; 2022 Mar; 177():106094. PubMed ID: 35074527
[TBL] [Abstract][Full Text] [Related]
7. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
8. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
[No Abstract] [Full Text] [Related]
9. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
[TBL] [Abstract][Full Text] [Related]
10. Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.
Xu L; Yu SQ; Gao L; Huang Y; Wu SS; Yang J; Sun YX; Yang ZR; Chai SB; Zhang Y; Ji LN; Sun F; Zhan SY
Biomed Environ Sci; 2020 Jan; 33(1):37-47. PubMed ID: 32029057
[TBL] [Abstract][Full Text] [Related]
11. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
[TBL] [Abstract][Full Text] [Related]
14. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Jin Y; Zhao H; Hou Y; Song G
Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
[TBL] [Abstract][Full Text] [Related]
17. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
[TBL] [Abstract][Full Text] [Related]
18. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
[TBL] [Abstract][Full Text] [Related]
19. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
